Clinical trial
Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic…
NCT00116506 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00116506 |
|---|---|
| Title | Study of Bevacizumab, Erlotinib, FOLFOX for Patients With Untreated Metastatic Colorectal Cancer |
| Official title | A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination With FOLFOX for Patients With Untreated Metastatic Colorectal Cancer |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Brigham and Women's Hospital Massachusetts General Hospital Beth Israel Deaconess Medical Center Genentech, Inc. Industry Sanofi-Synthelabo |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Neoplasm Metastasis |
| Intervention type | Drug |
| Interventions | erlotinib, FOLFOX, bevacizumab |
| Enrollment | 35 |
| Start date | Jan 1, 2005 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jun 30, 2005 |
| Last update posted | Dec 21, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: